Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Decreases By 84.3%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,751 shares, a decline of 84.3% from the June 15th total of 11,177 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 10,351 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MOLN. TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Wednesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Trading Down 2.4%

Shares of MOLN stock traded down $0.10 on Monday, reaching $3.92. The company had a trading volume of 1,363 shares, compared to its average volume of 10,246. The stock has a market cap of $158.49 million, a PE ratio of -2.02 and a beta of 1.08. The company has a 50-day moving average of $3.97 and a 200-day moving average of $4.26. Molecular Partners has a 12 month low of $3.41 and a 12 month high of $5.36.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). Sell-side analysts anticipate that Molecular Partners will post -1.28 earnings per share for the current year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.